BioCentury | Jan 6, 2017
Company News

Protagen, Novartis deal

Protagen said it used its SeroTag technology to successfully identify predictive and stratification biomarkers, which Novartis will use in the development of an undisclosed autoimmune drug. SeroTag uses high throughput screening to identify autoantibody biomarkers....
BioCentury | Aug 22, 2016
Company News

Protagen, Werfen deal

Protagen granted Werfen’s Inova Diagnostics Inc. company semi-exclusive rights to develop and commercialize biomarker bicaudal D homolog 2 (BICD2) , which Inova will add to its assay portfolio. The companies declined to disclose additional details. Protagen...
BioCentury | Jun 20, 2016
Company News

Protagen sales and marketing update

Protagen launched its Multilisa CENP-B, Multilisa Scl-70 and Multilisa BICD2 ELISA assays to diagnose systemic sclerosis. Multilisa CENP-B and Multilisa Scl-70 provide qualitative determination of IgG anti-centromer B and IgG anti-Scl-70 autoantibodies, respectively, in human...
BioCentury | Dec 21, 2015
Company News

Protagen, Mikrogen deal

Protagen and Mikrogen partnered to develop an in vitro diagnostic to distinguish between previously infected and newly infected patients with Lyme disease. Mikrogen, which identified a class of blood-based biomarkers using Protagen’s SeroTage technology, will...
BioCentury | Dec 22, 2014
Financial News

Protagen completes venture financing

Protagen AG , Dortmund, Germany Business: Diagnostic Date completed: 2014-12-16 Type: Venture financing Raised: Not disclosed Investors: Qiagen N.V. ; MIG Funds; NRW.Bank; company management Note: Protagen raised an undisclosed amount in the first tranche of...
BioCentury | Sep 1, 2014
Company News

Protagen sales and marketing update

Protagen launched ADx SSc Multilisa in the EU and North America to research scleroderma. The qualitative ELISA-based test kit uses Protagen’s SeroTag biomarker platform to detect autoantibody levels of topoisomerase I (TOP1) , centromere protein B...
BioCentury | Dec 9, 2013
Company News

Protagen, Pfizer deal

Protagen will use its SeroTag technology to discover prediction or patient stratification markers for an undisclosed autoimmune drug from Pfizer. SeroTag uses high throughput screening to identify autoantibody biomarkers. Pfizer declined to disclose details, and...
BioCentury | Dec 12, 2011
Company News

Protagen, Bayer deal

Protagen and Bayer's Bayer Healthcare Pharmaceuticals business partnered to clinically validate diagnostic biomarkers in endometriosis. Protagen will perform the clinical validation. Last year, the companies partnered to discover biomarkers to diagnose endometriosis using Protagen's UNIarray...
BioCentury | Aug 8, 2011
Company News

Protagen, SuppreMol deal

Protagen will use its UNIarray technology to identify autoantibody biomarkers associated with systemic lupus erythematosus (SLE) in patients enrolled in SuppreMol's ongoing Phase IIa trial of SM101 to treat SLE. UNIarray identifies auto-antibody signatures in...
BioCentury | Apr 4, 2011
Company News

Biogen Idec, Protagen deal

Protagen will use its UNIarray technology to find predictive and response biomarkers associated with multiple sclerosis (MS) therapy through a retrospective analysis of samples from a Biogen Idec clinical trial evaluating its MS drug Avonex...
Items per page:
1 - 10 of 37
BioCentury | Jan 6, 2017
Company News

Protagen, Novartis deal

Protagen said it used its SeroTag technology to successfully identify predictive and stratification biomarkers, which Novartis will use in the development of an undisclosed autoimmune drug. SeroTag uses high throughput screening to identify autoantibody biomarkers....
BioCentury | Aug 22, 2016
Company News

Protagen, Werfen deal

Protagen granted Werfen’s Inova Diagnostics Inc. company semi-exclusive rights to develop and commercialize biomarker bicaudal D homolog 2 (BICD2) , which Inova will add to its assay portfolio. The companies declined to disclose additional details. Protagen...
BioCentury | Jun 20, 2016
Company News

Protagen sales and marketing update

Protagen launched its Multilisa CENP-B, Multilisa Scl-70 and Multilisa BICD2 ELISA assays to diagnose systemic sclerosis. Multilisa CENP-B and Multilisa Scl-70 provide qualitative determination of IgG anti-centromer B and IgG anti-Scl-70 autoantibodies, respectively, in human...
BioCentury | Dec 21, 2015
Company News

Protagen, Mikrogen deal

Protagen and Mikrogen partnered to develop an in vitro diagnostic to distinguish between previously infected and newly infected patients with Lyme disease. Mikrogen, which identified a class of blood-based biomarkers using Protagen’s SeroTage technology, will...
BioCentury | Dec 22, 2014
Financial News

Protagen completes venture financing

Protagen AG , Dortmund, Germany Business: Diagnostic Date completed: 2014-12-16 Type: Venture financing Raised: Not disclosed Investors: Qiagen N.V. ; MIG Funds; NRW.Bank; company management Note: Protagen raised an undisclosed amount in the first tranche of...
BioCentury | Sep 1, 2014
Company News

Protagen sales and marketing update

Protagen launched ADx SSc Multilisa in the EU and North America to research scleroderma. The qualitative ELISA-based test kit uses Protagen’s SeroTag biomarker platform to detect autoantibody levels of topoisomerase I (TOP1) , centromere protein B...
BioCentury | Dec 9, 2013
Company News

Protagen, Pfizer deal

Protagen will use its SeroTag technology to discover prediction or patient stratification markers for an undisclosed autoimmune drug from Pfizer. SeroTag uses high throughput screening to identify autoantibody biomarkers. Pfizer declined to disclose details, and...
BioCentury | Dec 12, 2011
Company News

Protagen, Bayer deal

Protagen and Bayer's Bayer Healthcare Pharmaceuticals business partnered to clinically validate diagnostic biomarkers in endometriosis. Protagen will perform the clinical validation. Last year, the companies partnered to discover biomarkers to diagnose endometriosis using Protagen's UNIarray...
BioCentury | Aug 8, 2011
Company News

Protagen, SuppreMol deal

Protagen will use its UNIarray technology to identify autoantibody biomarkers associated with systemic lupus erythematosus (SLE) in patients enrolled in SuppreMol's ongoing Phase IIa trial of SM101 to treat SLE. UNIarray identifies auto-antibody signatures in...
BioCentury | Apr 4, 2011
Company News

Biogen Idec, Protagen deal

Protagen will use its UNIarray technology to find predictive and response biomarkers associated with multiple sclerosis (MS) therapy through a retrospective analysis of samples from a Biogen Idec clinical trial evaluating its MS drug Avonex...
Items per page:
1 - 10 of 37